 SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced positive Phase 1 clinical results and regulatory progress for two investigational small molecule therapeutics in development for the treatment of amyotrophic lateral sclerosis ALS at the 2021 Annual Northeast ALS NEALS Meeting being held virtually, October 6-7. 